Home » Stocks » Abeona Therapeutics

Abeona Therapeutics Inc. (ABEO)

Stock Price: $1.34 USD 0.07 (5.51%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $1.33 -0.01 (-0.75%) Oct 23, 6:19 PM

Stock Price Chart

Key Info

Market Cap 113.61M
Revenue (ttm) 482,000
Net Income (ttm) -94.97M
Shares Out 84.78M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.34
Previous Close $1.27
Change ($) 0.07
Change (%) 5.51%
Day's Open 1.27
Day's Range 1.25 - 1.37
Day's Volume 1,131,214
52-Week Range 1.00 - 5.19

More Stats

Market Cap 113.61M
Enterprise Value 14.96M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 84.78M
Float 67.90M
EPS (basic) -1.30
EPS (diluted) -1.31
FCF / Share -0.62
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.22M
Short Ratio 1.05
Short % of Float 3.28%
Beta 1.37
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 235.70
PB Ratio 0.94
Revenue 482,000
Operating Income -94.75M
Net Income -94.97M
Free Cash Flow -57.30M
Net Cash 98.65M
Net Cash / Share 1.16
Gross Margin -10,075.93%
Operating Margin -19,658.09%
Profit Margin n/a
FCF Margin -11,887.55%
ROA -23.87%
ROE -83.23%
ROIC -224.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(454.48% upside)
Current: $1.34
Target: 7.43
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-258.18%-5.85%-14.52%12.43%-54.7%-53.63%-
Gross Profit-3.000.840.891.040.931.924.14
Operating Income-77.09-58.17-27.84-23.88-18.55-3.13-3.80-4.32
Net Income-76.28-56.67-27.32-21.87-14.53-26.784.45-10.53
Shares Outstanding50.3547.5341.6434.1827.601.940.500.48
Earnings Per Share-1.51-1.19-0.66-0.64-0.53-15.263.04-25.91
Operating Cash Flow-62.82-39.11-22.66-13.01-10.42-1.61--3.96
Capital Expenditures-6.31-9.24-0.86-0.52-0.31---0.01
Free Cash Flow-69.13-48.35-23.52-13.53-10.73-1.61--3.97
Cash & Equivalents12984.9713869.1440.1411.520.420.40
Total Debt7.95----0.40--
Net Cash / Debt12184.9713869.1440.1411.120.420.40
Book Value17813417099.1067.724.82-14.78-17.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Abeona Therapeutics Inc.
Country United States
Employees 88

Stock Information

Ticker Symbol ABEO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ABEO
IPO Date September 19, 1980


Abeona Therapeutics, a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.